Although requiring additional research concerning the role and mechanism of action of BAZ1B in this context, these data reveal a new therapeutic vulnerability of endocrine therapy-resistant cancer cells, demonstrated by the effects of inhibition of the three factors on ERα expression and multiple key pathways essential for their growth, survival and invasion. Here, BAZ1B is linked to cancer.